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BACKGROUND: Chronic lymphocytic leukaemia (CLL) patients display a highly variable 
clinical course, with progressive acquisition of drug resistance. We sought to identify 
aberrant epigenetic traits that are enriched following exposure to treatment that could 
impact patient response to therapy. 
METHODS: Epigenome-wide analysis of DNA methylation was performed for 20 patients 
at two time-points during treatment. The prognostic significance of differentially methylated 
regions (DMRs) was assessed in independent cohorts of 139 and 163 patients. Their 
functional role in drug sensitivity was assessed in vitro. 
RESULTS: We identified 490 DMRs following exposure to therapy, of which 31 were CLL-
specific and independent of changes occurring in normal B-cell development. Seventeen 
DMR-associated genes were identified as differentially expressed following treatment in an 
independent cohort. Methylation of the HOXA4, MAFB and SLCO3A1 DMRs were 
associated with post-treatment patient survival, with HOXA4 displaying the strongest 
association. Re-expression of HOXA4 in cell lines and primary CLL cells significantly 
increased apoptosis in response to treatment with fludarabine, ibrutinib and idelalisib. 
CONCLUSION: Our study demonstrates enrichment for multiple CLL-specific epigenetic 
traits in response to chemotherapy that predict patient outcomes, and particularly implicate 




Chronic lymphocytic leukaemia (CLL) is marked by a highly variable clinical course, with 
some patients displaying indolent disease for many years, while others require immediate 
therapeutic intervention and have significantly inferior outcomes. One of the most 
informative prognostic biomarkers is somatic hypermutation levels of the immunoglobulin 
heavy chain variable region (IGHV), informing upon the cell of origin of the disease, with 
unmutated IGHV strongly associated with shorter time to first treatment and reduced 
survival.1 Other prognostic biomarkers including the expression of CD38 and ZAP70 have 
also been shown to predict patient outcome.2,3 Chromosomal abnormalities such as 
del(11q) and del(17p) are associated with aggressive disease and reduced survival, but 
are acquired during disease progression and rarely present at diagnosis.4 Currently, IGHV 
mutation and del(17p) or TP53 mutation are the only prognostic markers that inform upon 
the direction of treatment, and the biological mechanisms underlying treatment failure have 
not been elucidated. 
Recent advances in the field have demonstrated the expansion of genetic 
subclones during the progression of CLL,5 including selection for resistant subclones 
following therapeutic intervention.6 However, substantially less is understood about 
changes in the CLL epigenome associated with disease progression and response to 
treatment, and how this may influence patient outcomes. Similar to the acquisition of 
somatic mutations, epigenetic changes in CLL occur more frequently in late replication 
domains of the genome, and their acquisition appears to be stochastic.7 The changes 
observed in CLL strongly mirror those that occur during B-cell differentiation,8 with IGHV 
unmutated and mutated CLL cases displaying distinct global DNA methylation patterns.8–10 
Classification of patients based upon DNA methylation at five CpG sites has been shown 
to enable superior prediction of time to first treatment (TTT) and overall survival (OS) than 
IGHV status,11 demonstrating the potential cllinical utility of epigenetic biomarkers. 
 5
While previously believed to be highly stable after diagnosis,12 recent studies have 
demonstrated evolution of the CLL epigenome over time.7,13,14 Greater plasticity of the CLL 
epigenome is associated with the acquisition of genetic aberrations such as del(17p),13,15 
and worse patient outcomes such as shorter TTT.13 However, these studies have near-
exclusively described global phenomena in the epigenome rather than identifying gene-
specific changes, and therefore little is known about the acquired silencing or activation of 
genes implicated in response to therapy. In this study, we performed epigenome-wide 
analysis of DNA methylation to identify differentially methylated regions (DMRs) following 
exposure to therapy that may have utility as prognostic biomarkers and reveal genes with 
direct functional roles in chemosensitivity. We examined the association of the identified 
genes with patient prognosis in two independent cohorts, and used cell-line and primary 
CLL cell models to study their functional impact on chemosensitivity. Our study revealed 
multiple DMRs that predict the duration of patient survival following therapy, and in 
particular identify HOXA4 as an important regulator of sensitivity to multiple drugs used in 




Materials & Methods 
Patient samples & sample preparation 
An overview of the study approach and cohorts is provided in Supplementary Figure 1. 
The study was primarily performed within a cohort (‘Newcastle cohort’) of 163 CLL patients 
attending clinic at hospitals in the North-East of England (Freeman Hospital, Newcastle 
upon Tyne; Queen Elizabeth Hospital, Gateshead; and Sunderland Royal Hospital, 
Sunderland). The characteristics of the patients are provided in Supplementary Table 1. 
Data was collected on clinical characteristics and treatment history, and patient samples 
were analysed for IGHV mutational status, CD38 expression, and the presence of 
cytogenetic abnormalities (del(11q), del(13q), del(17p), and trisomy 12) and TP53 and 
ATM mutations. Peripheral blood samples were taken from patients with white cell counts 
of >30 x 109/L, from which mononuclear cells were isolated by density centrifugation using 
Lymphoprep media (Stem Cell Technologies) according to the manufacturer’s instructions. 
Genomic DNA was extracted from purified mononuclear cells using the Qiagen Blood and 
Tissue kit according to the manufacturer’s instructions. 
 
Epigenome-wide analysis of DNA methylation 
The identification of leukaemia-specific DMRs was performed within the discovery cohort 
(n=20), nested within the wider Newcastle cohort that was used for prognostic validation. 
Samples at multiple timepoints were available for a total of 42 of the 163 patients within 
the Newcastle cohort (median time between samples: 26.9 months). Samples were 
collected from patients presenting at clinic with white cell counts of >30 x 109/L, and were 
selected to include patients who had received treatment between sampling, as well as 
those who remained treatment naïve. Of these 42 patients, 24 underwent treatment with 
fludarabine or chlorambucil between sampling, while 18 had stable disease and underwent 
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no treatment. For DMR discovery, we utilised paired samples from 20 of the patients 
undergoing treatment and 4 who remained untreated. Clinical information for these 
patients is provided in Supplementary Table 2. In the absence of specific cell counts, B-
cell composition of the samples was estimated by the Houseman method adapted by 
Horvath.16,17 The median B-cell composition was 95.4% (95% confidence interval (CI): 
92.2-95.8). 
Epigenome-wide analysis of DNA methylation at two timepoints was conducted 
using the Illumina HumanMethylation450 BeadChip platform, performed at the Edinburgh 
Clinical Research Facility, University of Edinburgh (United Kingdom), using 500 ng of DNA 
that was bisulfite-converted using the EZ DNA Methylation-Gold kit (Zymo Research) 
according to the manufacturer’s instructions. The data was processed in R using the 
Bioconductor package minfi, and differentially methylated regions were identified using the 
DMRcate package18 with p-values adjusted for multiple hypothesis testing by the 
Benjamini-Hochberg method. CLL-specific DMRs were identified by use of DNA 
methylation microarray data from matched purified samples of naïve and class-switched 
memory B-cells from the study of Kulis et al,10 thereby enabling differentiation of CLL-
specific methylation changes from those also seen during B-cell development. 
 
Validation cohort 
DMRs identified in the discovery cohort were taken forward for examination in a validation 
cohort using publicly-available Illumina HumanMethylation450 microarray data from the 
study of Tsagiopoulou et al,14 available through ArrayExpress (E-MTAB-7575). Paired 
samples from 34 patients taken prior to treatment and at relapse were used to examine 
changes in methylation at the 32 DMRs by paired t-test, with p-values adjusted for multiple 
hypothesis testing by the Benjamini-Hochberg method. 
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Analysis of gene expression 
The impact of epigenetic changes at CLL-specific DMRs was examined using Affymetrix 
Human Genome U133 Plus 2.0 gene expression microarray data from the study of Landau 
et al,5 available through Gene Expression Omnibus (GSE37168). Data was leveraged 
from 13 patients for whom paired samples were taken prior to treatment and then at 
relapse following therapeutic intervention. Differential expression between time-points was 
examined by paired t-test, with p-values adjusted for multiple hypothesis testing by the 
Benjamini-Hochberg method. The correlation between DMR methylation and gene 
expression was assessed using paired DNA methylation and gene expression microarray 
data from a cohort of 139 CLL patients available through the International Cancer Genome 
Consortium (ICGC). 
 
Assessment of patient prognosis 
The potential prognostic relevance of the validated DMRs was first examined using DNA 
methylation microarray data from the 139 CLL patients within the ICGC cohort, for which 
samples were reported to comprise >95% neoplastic cells.10 Leading candidates were 
taken forward for further analysis within the Newcastle cohort (n=163), following analysis 
of DMR methylation by pyrosequencing. Associations with post-treatment survival (i.e. 
time between first treatment to death or last follow-up) were determined by Cox 
proportional hazards regression. Patients were stratified into high and low methylation 
categories for each DMR by ROC curve analysis using log2-transformed methylation 
values, with the optimal threshold determined by the Youden index (sensitivity + specificity 





Locus-specific analysis of HOXA4 promoter methylation within the Newcastle cohort was 
performed by pyrosequencing. Samples from 163 patients were analysed (Supplementary 
Table 1), with sequential samples from 18 patients who remained treatment naïve at the 
time of the second sample used to confirm the specificity of DMR selection to therapeutic 
intervention. 100 ng of DNA was bisulfite-modified using the Methylamp DNA modification 
kit (Epigentek) according to the manufacturer’s instructions, and the promoter region PCR-
amplified using 1 µl of modified DNA. PCR products were prepared according to the 
manufacturer’s instructions and analysed on a PyroMark Q96 MD pyrosequencer 
(Biotage). The primer sequences used have been described previously.19 Analysis was 




The Raji cell line, a differentiated B-cell cell line derived from a patient with Burkitt’s 
lymphoma, was authenticated by STR profiling (NewGene, Newcastle upon Tyne, UK). 
Cells were cultured in RPMI 1640 media with 10% foetal calf serum. Primary CLL cells 
from patients within the Newcastle cohort were seeded on to a feeder layer of CD40L-
expressing mouse fibroblast cells (a gift from Professor Chris Pepper, Brighton & Sussex 
Medical School) that were irradiated (30 Gy) to induce mitotic arrest, and then cultured in 




The impact of HOXA4 expression upon drug sensitivity was analysed by lentiviral-based 
overexpression of the gene in Raji cells. This differentiated B-cell cell line was selected 
due to significantly superior transduction efficiency in comparison to the MEC1 chronic 
lymphocytic leukaemia cell line. Furthermore, Raji cells were more appropriate to examine 
drug response due to the relative insensitivity of MEC1 cells to clinically-relevant doses of 
fludarabine due to a TP53 mutation.20,21 Cells were transduced using 100 µl of lentivirus 
(pSINE-SIEW vector, a gift from Dr Paul Sinclair, Newcastle University Centre for Cancer, 
UK) that was concentrated 30-fold using Lenti-X solution (Clontech), and 8 mg/ml 
polybrene. Cells were washed in PBS after 24 hours, and the efficiency of transduction 
measured by assessment of GFP expression by flow cytometry at Day 5. 
Primary CLL cells were transduced using 500 µl of lentivirus and 8 mg/ml 
polybrene, before seeding on to the feeder layer after incubation for four hours. The 
efficiency of transduction was measured by flow cytometry-based analysis of GFP 
expression at Day 5. 
 
Drug sensitivity 
Transduced cells were treated with 1–50 µM of fludarabine (Sigma Aldrich), ibrutinib (Enzo 
Life Sciences) or idelalisib (Selleck Chemicals). Apoptosis was measured at 48 hours 
using the Annexin V PE Apoptosis Detection Kit I (BD Biosciences) in conjunction with flow 
cytometry, using the BD FACSCanto II (BD Biosciences). Transduced primary CLL cells 
from three patients within the Newcastle cohort were grown on a CD40L-expressing feeder 
layer for six days prior to drug treatment. Experiments were performed in triplicate, and the 




Correlations between DMR methylation and gene expression were assessed by Spearman 
rank correlation. Associations of HOXA4 methylation with cytogenetic abnormalities and 
IGHV status were identified by Fisher’s exact test, and correlations with IGHV sequence 
homology determined by Spearman rank correlation. Differences in HOXA4 methylation by 
Binet stage were determined by Mann-Whitney U test, and associations with post-
treatment and overall survival were identified by Cox proportional hazards regression as 
previously described. Differential drug sensitivity and cell proliferation in transduced 
HOXA4-overexpressing cells were analysed by Mann-Whitney U test. All analyses were 
performed in R (version 3.2.5) and GraphPad Prism (GraphPad Software, version 7.0b). 





Identification of differentially methylated regions following treatment 
An outline of the study is shown in Supplementary Figure 1. Firstly, to identify DMRs 
occurring in response to therapy, epigenome-wide analysis of DNA methylation was 
performed on 20 patients at 2 time-points during treatment. The patients were nested 
within the Newcastle cohort of 163 patients attending clinic in the North-East of England 
(Supplementary Table 1). The median time between sampling (time-points ‘A’ and ‘B’) was 
31.1 months. Further characteristics of the patients used for DMR discovery are provided 
in Supplementary Table 2. 
Regional changes in methylation during the course of treatment were identified 
using the DMRcate approach.18 We restricted the output to DMRs with a maxbetafc 
(largest mean change in methylation, β, at a single CpG site) of >0.04 and with 
PFDR<0.005 within the region, which revealed 551 loci. We then selected for DMRs 
mapping to loci within 1500 bases of the transcriptional start site or within the 5’UTR or 
first exon. A total of 490 DMRs were retained, each comprising 2–55 CpG sites, of which 
433 were hypermethylated and 57 hypomethylated (Supplementary Table 3). 
Pyrosequencing-based validation of five DMRs confirmed the findings of the arrays 
(Supplementary Figure 2).  
 
Leukaemia-specific acquisition of epigenetic traits 
It has recently been demonstrated that most methylation changes observed in CLL also 
occur during the later stages of B-cell differentiation.13 To reveal epigenetic changes more 
likely to be directly implicated in CLL pathobiology, we excluded regions that are 
differentially methylated during B-cell development. For this purpose, we utilised publicly-
available methylation microarray data from naïve and memory B-cells, obtained from the 
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study of Kulis et al.10 The majority of identified changes occurring during treatment were 
mirrored by similar changes between naïve and class-switched memory B-cells (Figure 
1A). Our analysis revealed 32 DMRs that were putatively specific to CLL (Table 1, 
Supplementary Figure 3), being either unchanged (Δβ<0.04) in B-cell development (28 
DMRs) or displaying an inverse change (4 DMRs).  Of these, 27 displayed increased 
methylation and 5 reduced methylation in CLL following treatment (Figure 1B). Changes in 
methylation were highly correlated between the DMRs (Figure 1C), with a median absolute 
correlation (r) of 0.51. To further restrict our analysis to DMRs that are specifically selected 
for during treatment, we examined methylation of the 32 DMRs in sequential samples from 
4 patients who remained untreated between sampling. Only 1 of the 32 DMRs, which 
mapped to the P2RY1 gene, displayed a significant change in methylation among 
untreated patients and was subsequently excluded from further analysis. 
While the mean changes in methylation (β) across all patients were moderate (-
0.05–0.08; Table 1), a high degree of interpatient variability was observed at each DMR, 
as some patients displayed large alterations in methylation (max Δβ: 0.51) while others 
displayed no changes between the time-points. This is exemplified by 6 patients displaying 
differential methylation of Δβ>0.10 at 11-20 DMRs, while 10 patients displayed such 
changes at only a single locus or not at all (Figure 1D). Therefore, it is important to 
emphasise that epigenetic changes at these DMRs do not represent moderate alterations 
in methylation uniformly observed among all patients, but rather they are loci that are 
variably differentially methylated between individuals. Importantly, the magnitude of 
changes in methylation were not significantly associated with the time between sampling 
for any of the DMRs (Spearman’s rank correlation; PFDR: 0.25-0.82). Furthermore, patients 
who had previously been treatment naïve (n=7) displayed no significant difference in 
response at any of the DMRs in comparison to those who had previously been treated 
(n=13) (Mann Whitney U test, PFDR>0.90). 
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Unsupervised hierarchical clustering identified 12 patients displaying changes in 
DNA methylation across the 31 DMRs following therapy (‘Dynamic’) while 8 displayed 
highly stable methylation signatures (‘Stable’) (Figure 1D). 11q deletions were exclusively 
observed among Dynamic patients (5 of 12) and never among the 8 Stable patients 
(Fisher’s exact test, p=0.055). No association was observed for the Dynamic group with 
either IGHV status (p=1.00) or 17p deletions (p=0.16). There was no enrichment among 
the groups for patients who were treatment naïve at timepoint A (Fisher’s exact test, 
p=0.64). 
 
Examination of CLL-specific DMRs in the validation cohort 
We performed validation of the 31 CLL-specific DMRs using publicly-available DNA 
methylation microarray data taken from 34 patients prior to first treatment and again at 
relapse.14 The median time between samples was 30 months, and patients were near-
exclusively treated with FCR. There was a high degree of correlation in the mean 
methylation changes observed at the 31 DMRs in the discovery and validation cohorts (r = 
0.68, p<0.0001) (Figure 1E), with 19 showing significant differences in methylation 
between first treatment and relapse, and a further three approaching significance 
(PFDR<0.085) (Table 1). 
 
Differential expression of DMR-associated genes 
To examine changes in the expression of DMR-associated genes following therapy, we 
utilised publicly-available paired gene expression data from 13 patients taken before 
treatment and following chemotherapeutic intervention at the point of relapse (GSE37168). 
The median time between samples was 42 months, and the patients were primarily treated 
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with fludarabine-based regimens.5 Of the 22 validated CLL-specific DMRs, 16 associated 
genes were differentially expressed between timepoints (PFDR<0.05), while a further gene, 
RNF144A, approached significance (PFDR<0.10). Twelve of these showed decreased 
expression (ADAMTS17, CDK6, DAGLA, DST (BEND6 DMR), FGF12, FZD8, HOXA4, 
KCNMA1, MBOAT2, MYRIP, RNF144A and TIAM1; Figure 2A-E and Supplementary 
Table 4) and five showed increased expression (GJA3, JAKMIP1, MAFB, SLCO3A1 and 
ZNF503; Figure 2F). Although promoter methylation is typically associated with inhibition 
of gene expression, approximately 30% of correlations between promoter methylation and 
gene expression are positive ones (as observed here).22 Interestingly, CDK6 and TIAM1 
displayed simultaneous significant up-regulation and down-regulation of transcripts 
measured by different probes, suggesting an impact of chemotherapy upon transcript 
usage. Four genes displayed no significant change (ADRA1B, CCSER1 (FAM190A DMR), 
HIST3H2A, and POMGNT2 (C3orf39 DMR)), while FLJ42289 could not be assessed due 
to no expression data being available. 
Taken together, we identified 17 genes that demonstrate CLL-specific differential 
methylation and expression in patients following exposure to chemotherapy, as 
concurringly observed in three independent cohorts (details of the DMRs available within 
Supplementary Figure 4). To further explore the functional basis of our observations, we 
assessed correlations between DMR methylation and gene expression using data from 
139 CLL patients available through the ICGC. Five DMRs showed a significant correlation 
with gene expression (CDK6, DST (BEND6 DMR) DAGLA, SLCO3A1 and ZNF503; 
P<0.05) and a further four approached significance (ADAMTS17, HOXA4, MAFB and 
MYRIP; P<0.10). All exhibited negative correlations between DMR methylation and gene 
expression with the exception of DAGLA. It is known that CpG sites in close proximity to 
one another can exhibit conflicting associations with gene expression,22 which may explain 
discrepancies with our previous observations of changes in gene expression following 
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chemotherapy. We noted reduced variation and lower levels of expression of the genes 
within the ICGC cohort in comparison to GSE37168, which may have impaired the ability 
to identify correlations at some other loci. 
 
Impact of DMR methylation upon post-treatment survival 
The prognostic significance of the 9 DMRs with confirmed correlation between methylation 
and gene expression was examined in the same 139 CLL patients within the ICGC 
cohort.10 We examined methylation at each of the DMRs, here measured in early/pre-
treatment samples, to determine association with post-treatment survival (i.e. the duration 
of survival after the initiation of therapy). We identified three DMRs that were significantly 
associated with patient post-treatment survival by univariate analysis: HOXA4; MAFB; and 
SLCO3A1 (Table 2; Figure 3A-C). Each displayed increased methylation in the discovery 
and validation cohorts, and hypermethylation was associated with reduced post-treatment 
survival in the ICGC cohort. A further three approached significance (ADAMTS17, CDK6, 
and MYRIP). Therefore, our analyses identified three prognosis-associated DMRs that 
represent adverse epigenetic traits enriched during disease progression. The strongest 
effect on survival was with the HOXA4 DMR, with hypermethylation associated with a 
~3.5-fold increased risk of death following treatment. 
 
Examination of prognosis-associated DMRs 
We selected two of the prognosis-associated DMRs for further examination based upon 
plausible biological roles in mediating patient response to therapy. HOXA4 is a homeobox 
gene that encodes a transcription factor involved in development, and it has previously 
been reported as hypermethylated in CLL23 and is associated with imatinib resistance 
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among chronic myeloid leukaemia patients.24 SLCO3A1 encodes an anion transporter that 
may be implicated in drug uptake. 
 Examination of SLCO3A1 DMR methylation in patient samples within the discovery 
cohort revealed a significant correlation with gene expression, but re-expression of the 
gene in the malignant B-cell lines NALM6 and SEM did not significantly impact upon their 
sensitivity to fludarabine (Supplementary Figure 5), thereby suggesting that SLCO3A1 re-
expression in isolation has little impact on drug sensitivity. 
 
HOXA4 hypermethylation and patient characteristics 
To investigate the role of HOXA4 in CLL and explore how it relates to the progression of 
the disease, we first analysed HOXA4 promoter methylation by pyrosequencing in the 
Newcastle cohort (n=163). Higher methylation levels were associated with reduced post-
treatment survival (Figure 3D) and overall survival (Figure 3E) (p=0.03 and p=0.03 
respectively), supporting the association with post-treatment survival previously observed 
in the ICGC cohort. We also identified a progressive increase in methylation with the 
progression of the disease (Figure 3F). Median methylation levels increased from 62% 
among Binet Stage A patients to 65% at Stage B and 74% at Stage C, with the difference 
between Stage A and Stage C patients statistically significant (Mann Whitney U test, 
p=0.03). HOXA4 hypermethylation was significantly associated with IGHV sequence 
homology (r=0.34, p<0.0001) and with 11q deletions (Fisher’s exact test, p=0.001), but not 
13q and 17p deletions (p=0.63 and p=0.79 respectively) or CD38 expression (r= -0.005, 
p=0.97) (Supplementary Table 5). 
Among these 163 patients, sequential samples were available from 18 patients who 
underwent no treatment between the timepoints. Pyrosequencing-based analysis revealed 
HOXA4 methylation to be stable among these untreated patients (Figure 3G), in contrast 
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to our previous observation of significantly increased methylation in response to treatment 
within the discovery cohort. These data provide further evidence that changes in HOXA4 
methylation are selected for in patients following exposure to therapy. 
 
Re-expression of HOXA4 increases sensitivity to multiple drugs used in CLL 
therapy 
To determine whether HOXA4 expression confers sensitivity to therapy, we used a 
lentiviral system to express HOXA4 in Raji cells (Figure 4A). Re-expression of HOXA4 in 
transduced Raji cells was confirmed by qPCR (Supplementary Figure 6). We observed 
significantly increased apoptosis (p<0.05) in HOXA4-expressing cells 48 hours after 
treatment with 3-10 µM fludarabine (Figure 4B), 1-30 µM ibrutinib (Figure 4C) and 1-50 µM 
idelalisib (Figure 4D) in comparison to control cells transduced with an empty vector. 
Higher levels of apoptosis were also observed in untreated cells, but the increased 
sensitivity to drug exposure remained significant even after correction for this effect 
(Supplementary Fig 7), indicating that re-expression increases sensitivity to fludarabine, 
Ibrutinib and idelalisib. 
To confirm that the observations in Raji cells were relevant to CLL, we transduced 
primary CLL cells from three patients with HOXA4-expressing and control lentiviral 
constructs. Primary cells were maintained on a feeder layer and then treated with 3 and 10 
µM fludarabine. We observed significantly higher levels of apoptosis at both drug 
concentrations in primary CLL cells expressing HOXA4 in comparison to control cells 
(p=0.02 and p<0.01 respectively; Figure 4E), confirming that re-expression of HOXA4 
increases drug sensitivity in primary CLL cells.  
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Discussion 
The chronic lymphocytic leukaemia epigenome was previously considered to be highly 
stable throughout the course of the disease,12 but it is increasingly recognised that it is 
dynamic.13 CLL is now understood to show selection for subclonal genetic aberrations with 
its progression,5 and our study has, for the first time, identified similar enrichment of 
abnormal gene-specific epigenetic traits that may be key to understanding patient 
response to therapy. Indeed, as it is still commonly perceived to be an incurable disease, 
elucidating the acquisition and effect of adverse genetic and epigenetic traits provides 
crucial insight into how the disease develops resistance to chemotherapy. Here, we have 
identified genes that are differentially methylated and expressed following exposure to 
therapy and that are associated with post-treatment survival. In particular, we have 
identified enrichment for the epigenetic silencing of HOXA4 that reduces the sensitivity of 
leukaemic cells to therapy and thereby impairs patient survival. To the best of our 
knowledge, ours is the first study to identify enrichment for locus-specific epigenetic traits 
following treatment that may predict patient outcome following initiation of therapy. 
There is increasing evidence for evolution of the CLL epigenome during disease 
progression,7,14 with global trends in DNA methylation associated with the acquisition of 
genetic aberrations.13,15 These epigenetic changes are typically moderate, even when 
associated with progression from indolent disease to a more aggressive form requiring 
therapeutic intervention.25 Furthermore, many of these loci are also differentially 
methylated in B-cell development, with the CLL epigenome more closely resembling that 
of class-switched memory B-cells than naïve ones, regardless of IGHV status.10,25 Indeed, 
it is increasingly recognised that the overwhelming majority of the epigenetic changes 
observed in CLL are also seen during B-cell development.8,13 A recent examination of 31 
genes previously reported to be hypermethylated in CLL across nine studies revealed that 
all but one gene, HOXA4, show similar hypermethylation during B-cell development.8 
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Consistent with this, we observed that most loci undergoing epigenetic changes during 
treatment were not unique to CLL. Unusually for terminally differentiated cells, B-cells 
retain the ability to divide and thus it may be that these methylation changes are reflective 
of B-cell proliferation, irrespective of differentiation state or transformation. We therefore 
took steps to identify alterations unique to CLL in order to identify genes that may be 
directly implicated in response to therapy. 
We have previously identified epigenetic dysregulation of HOXA4 in both myeloid 
and lymphoid leukaemias23,26 and reported that hypermethylation of HOXA4 is associated 
with poor response to imatinib in chronic myeloid leukaemia.23,24 Here, we have built on 
these observations to reveal enrichment for HOXA4 hypermethylation during the course of 
CLL patient treatment and disease progression, and to provide the first evidence that loss 
of HOXA4 expression reduces the sensitivity of malignant B-cells to multiple 
chemotherapeutic agents. Given the variable mechanisms of action of these drugs 
(fludarabine, ibrutinib and idelalisib), this suggests a broad anti-survival effect of the gene 
as opposed to a drug-specific one. This hypothesis is further supported by our observation 
of increased apoptosis in untreated cells expressing HOXA4 in comparison to those that 
do not express it, implying activation of pro-survival signaling. Recent work in lung cancer 
cell lines has demonstrated that expression of HOXA4 inhibits cell survival via inhibition of 
the Wnt signalling pathway,27 a pathway known to be activated in CLL28 and which 
promotes the survival of leukaemic cells.29 Negative regulators of Wnt signalling are 
epigenetically silenced in CLL,30 and our study may implicate HOXA4 as another silenced 
inhibitor. This is further supported by the observation of frequent hypermethylation of the 
HOXA cluster and hypomethylation of Wnt ligands in CLL patient samples.31 
Subsequently, subclonal cell populations with biallelic methylation of HOXA4 would be 
selected for due to the increased pro-survival Wnt signalling, with selection pressure 
significantly increased with therapeutic intervention. 
 21
Previous studies have identified genetic aberrations present at low frequencies in 
early stage CLL that already enable prediction of patient prognosis,32,33 and the expansion 
of such subclones following therapeutic intervention.5 Our study has similarly identified 
DNA methylation at three DMRs, including HOXA4, that when measured in early disease 
are able to predict post-treatment survival, consistent with the expansion of subclones with 
altered methylation that were already present prior to exposure to therapy. We have also 
provided further evidence to support the hypothesis that the epigenome displays co-
evolution with genetic aberrations.13 Locally disordered methylation is enriched in patients 
displaying genetic evolution,7 and a recent study of 13 patients demonstrated expansion of 
genetic subclones only among those also displaying concordant changes in DNA 
methylation over time, irrespective of IGHV subtype.34 Our results may suggest a potential 
association between patients with dynamic DNA methylation patterns and the acquisition 
of 11q deletions, an important marker of impaired survival and consistent disease 
progression.35 Our further observation of an association between HOXA4 
hypermethylation and 11q deletions is likely to be driven by this correlation with Dynamic 
cases, as it is unlikely that the two are causally linked. However, we were unable to 
confirm this association in the validation cohort (Fisher’s exact test, p=0.71) and therefore 
it is not yet clear if this is a phenomenon in CLL or a cohort-specific observation. Further 
work is required to elucidate the possible relationship between dynamic epigenetic profiles 
and 11q deletions, especially as no significant association was observed with 17p 
deletions, thereby implying there may be a more complex mechanism than general 
genomic instability. Interestingly, no association was present between IGHV mutational 
status and dynamic epigenetic profiles. This is in contrast to work of Oakes et al13 that 
suggested epigenomic heterogeneity and evolution are more common among higher-risk 
IGHV unmutated cases, but supported by the observations of Smith et al25 that 
differentially methylated loci in disease progression are not correlated with IGHV status. 
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The inherent variability between CLL patients in disease progression and treatment 
represents a significant challenge in its study. The heterogeneity in treatment types and 
histories among the patients used for DMR discovery represents a potential limitation in 
our analysis, but it has not prohibited the identification of DMRs following therapeutic 
intervention that were validated in independent cohorts. Furthermore, it ensures that the 
aberrant epigenetic traits identified in our study are of broad translational relevance and do 
not represent drug-specific effects, as supported by our in vitro findings of increased 
sensitivity to three chemotherapeutic agents with HOXA4 expression. A particular strength 
of our study is the use of transduced cell-lines and primary CLL cells to assess the effect 
of HOXA4 overexpression upon drug sensitivity. Examination of patient samples simply 
categorised by HOXA4 methylation level would be subject to the extensive interpatient 
heterogeneity for other factors that could influence drug response, but the use of a 
lentiviral system has enabled a more controlled and direct study of the effect of HOXA4 
expression. 
Our study has for the first time provided evidence for enrichment of locus-specific 
epigenetic traits in CLL following therapeutic intervention that are associated with patient 
outcome. In particular, we have identified epigenetic silencing of HOXA4 as implicated in 
reduced sensitivity to therapy. Further work is required to delineate patient response by 
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Table 1: Differentially methylated regions in CLL following treatment. The 31 CLL-specific 
DMRs are listed with a description of the genomic region (Human GRCh37/hg19 genome 
build), the number of CpG sites mapping to the DMR, and the minimum p value (minpval) 
and largest mean change in methylation observed at individual CpG sites within the DMR 
(maxbetafc). The DMRs are ranked by the mean methylation change between time-points 
(i.e. Δβ) in the discovery cohort, with the mean methylation levels (β) at the entry (A) and 
follow-up (B) time-points displayed for both the discovery and validation cohorts. 
 
Table 2: Associations of DMR methylation and patient post-treatment survival. Univariate 
analysis of post-treatment survival in the ICGC cohort by methylation of the nine CLL-
specific DMRs that were identified as differentially expressed following therapeutic 
intervention and displaying significant correlations between methylation and gene 
expression. The DMRs are ranked by hazard ratio (HR, with 95% confidence intervals), 
with significant results (PFDR<0.05) highlighted in bold and by an asterisk.  
 
Figure 1: Characterisation of CLL-specific DMRs. A: Venn diagram illustrating the 
similarities in methylation changes during B-cell differentiation and in CLL patients during 
the course of treatment. B: methylation at six representative DMRs in normal CD19+ B-
cells from 14 healthy individuals (‘Healthy’; red) and 20 CLL patients at time-points A 
(‘CLL_A’; blue) and B (‘CLL_B’; green). C: correlation plot of changes in methylation (Δβ) 
at the 32 CLL-specific DMRs. Squares are coloured by median correlation values (r), with 
positive correlations in blue and negative correlations in red. D: heatmap displaying 
changes in methylation at the 31 treatment-specific DMRs in 20 CLL patients undergoing 
treatment (T_01 – T_20) and 4 who remained untreated (Un_01 – Un_04) between time-
 31
points A and B, and changes in B-cell development from naïve to memory class-switched 
(Bcell_1 – Bcell_3). Increases in methylation are displayed in red, and decreases in blue. 
IGHV unmutated cases are indicated in purple and IGHV mutated cases in yellow, with 
11q deletions (light green) and 17p deletions (pink) also indicated. Patients were classified 
as having stable (brown) or dynamic (turquoise) epigenetic patterns by hierarchical 
clustering. E: correlation in mean differential methylation of the 31 DMRs observed in the 
discovery and validation cohorts. Circles represent DMRs and are shaded according to 
statistical significance as indicated, with a line of identity (dashed line). 
 
Figure 2: Differential expression of DMR-associated genes in the validation cohort. 
Analysis of the expression (log2 transformed) of FZD8 (A), DST (BEND6 DMR) (B), 
MBOAT2 (C), HOXA4 (D), TIAM1 (E) and MAFB (F) in samples taken from 13 patients 
prior to chemotherapy and at relapse in the validation cohort (GSE37168). Lines indicate 
samples from the same patient. 
 
Figure 3: Associations between DMR methylation and patient prognosis. A-C: Kaplan-
Meier plots for post-treatment survival in patients within the ICGC cohort (n=139) stratified 
by methylation level (high/low) of HOXA4 (A), SLCO3A1 (B) and MAFB (C). D-G: 
pyrosequencing-based analysis of HOXA4 methylation within the Newcastle cohort 
(n=163). Kaplan-Meier plots for post-treatment survival (D) and overall survival (E) by 
HOXA4 methylation (high/low). HOXA4 methylation by Binet stage (F), with lines indicating 
median values, boxes the interquartile range (IQR), whiskers the highest and lowest 
values within 1.5*IQR, and outliers displayed as individual points. HOXA4 methylation at 
sequential time-points among 18 untreated patients (G), with lines indicating samples from 
the same patient. 
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Figure 4: HOXA4 expression is associated with increased drug sensitivity. A: diagrammatic 
representation of the lentiviral construct used to transduce Raji and primary CLL cells. The 
SFFV promoter, HOXA4 gene, internal ribosomal entry site (IRES) and green fluorescent 
protein (GFP) gene are indicated. B-D: drug sensitivity of control (empty vector) and 
HOXA4-expressing transduced Raji cells in response to treatment with fludarabine (B), 
ibrutinib (C) and idelalisib (D). Apoptosis was measured 48 hours after drug treatment by 
detection of Annexin V by flow cytometry. Mean values are displayed, with error bars 
indicating standard error of the mean. E: sensitivity of primary CLL cells transduced to 
express HOXA4 to fludarabine treatment (n=3). Apoptosis was measured 48 hours after 
drug treatment by detection of Annexin V by flow cytometry. Mean values are displayed, 
with error bars corresponding to standard error of the mean. Statistical significance is 
indicated (* = p<0.05; ** = p<0.01; *** = p<0.005; **** = p<0.001).  
Table 1: Differentially methylated regions in CLL following treatment 
Gene DMR Probes Minpval Max. β value 
change Discovery Validation 
     
A B Mean 
diff A B 
Mean 
diff pFDR 
BEND6 chr6:56819429-56819432 2 1.45 x 10-4 0.08 0.49 0.57 0.08 0.54 0.62 0.09 0.0482 
ADAMTS17 chr15:100881458-100882165 4 5.53 x 10-5 0.10 0.40 0.47 0.07 0.49 0.56 0.07 0.0248 
HIST3H2A chr1:228645462-228645634 7 2.04 x 10-9 0.08 0.22 0.28 0.06 0.28 0.33 0.05 0.0248 
FGF12 chr3:192127330-192127457 3 4.11 x 10-6 0.07 0.16 0.21 0.05 0.17 0.25 0.08 0.0248 
GJA3 chr13:20735337-20735532 3 2.00 x 10-4 0.06 0.10 0.16 0.05 0.12 0.14 0.02 0.0562 
HOXA4 chr7:27169957-27170554 8 2.41 x 10-4 0.10 0.60 0.65 0.05 0.59 0.63 0.04 0.0075 
JAKMIP1 chr4:6201080-6202384 7 4.28 x 10-6 0.09 0.32 0.37 0.05 0.32 0.38 0.06 0.0482 
MAFB chr20:39317034-39318100 5 4.46 x 10-9 0.08 0.29 0.34 0.05 0.29 0.33 0.04 0.0301 
RNF144A chr2:7057153-7057945 7 1.61 x 10-4 0.07 0.24 0.29 0.05 0.32 0.40 0.07 0.0248 
ZNF503 chr10:77161647-77161653 3 2.11 x 10-7 0.06 0.14 0.18 0.05 0.18 0.22 0.04 0.0482 
ADRA1B chr5:159343275-159343549 4 4.24 x 10-4 0.05 0.16 0.19 0.04 0.19 0.23 0.04 0.0248 
C3orf39 chr3:43146909-43147587 6 1.50 x 10-6 0.06 0.25 0.28 0.04 0.27 0.30 0.03 0.0248 
CDK6 chr7:92462202-92463218 5 2.41x 10-6 0.05 0.13 0.17 0.04 0.23 0.25 0.02 0.0482 
DAGLA chr11:61447834-61447938 4 4.42 x 10-4 0.04 0.18 0.21 0.04 0.12 0.15 0.03 0.0248 
FAM190A chr4:91047852-91049533 11 3.83 x 10-8 0.08 0.19 0.22 0.04 0.20 0.23 0.03 0.0699 
FLJ42289 chr15:100890243-100890462 6 1.33 x 10-7 0.06 0.19 0.23 0.04 0.26 0.31 0.05 0.0248 
ID2 chr2:8822058-8822738 4 1.30 x 10-6 0.05 0.16 0.20 0.04 0.22 0.23 0.01 0.2915 
KCNMA1 chr10:79397346-79398415 6 3.31 x 10-6 0.06 0.18 0.22 0.04 0.20 0.24 0.04 0.0848 
FZD8 chr10:35929604-35931235 11 1.23 x 10-4 0.05 0.16 0.18 0.03 0.19 0.22 0.04 0.0482 
KIF26B chr1:245318209-245318335 5 5.95 x 10-4 0.06 0.09 0.12 0.03 0.14 0.14 0.00 0.9860 
MBOAT2 chr2:9143747-9144505 7 3.14 x 10-4 0.04 0.17 0.19 0.03 0.19 0.22 0.03 0.0248 
MSC chr8:72754953-72757004 17 3.64 x 10-9 0.05 0.22 0.26 0.03 0.27 0.30 0.02 0.1298 
MYRIP chr3:39850280-39851931 12 2.43 x 10-6 0.06 0.17 0.21 0.03 0.19 0.23 0.04 0.0475 
SAMD12 chr8:119634283-119634612 5 4.70 x 10-4 0.05 0.15 0.18 0.03 0.19 0.21 0.02 0.2383 
SLCO3A1 chr15:92396240-92397541 9 1.31 x 10-8 0.11 0.12 0.15 0.03 0.15 0.20 0.06 0.0248 
TIAM1 chr21:32931471-32931935 3 1.03 x 10-4 0.05 0.09 0.13 0.03 0.11 0.15 0.04 0.0345 
GABBR1 chr6:29600994-29602034 7 1.98 x 10-4 -0.05 0.16 0.13 -0.03 0.12 0.11 -0.01 0.4471 
ZAP70 chr2:98329337-98330020 7 1.66 x 10-4 -0.04 0.22 0.19 -0.03 0.17 0.17 0.00 0.4667 
MYOM2 chr8:1993545-1993893 2 2.64 x 10-4 -0.05 0.33 0.29 -0.04 0.35 0.35 0.00 0.9860 
PNOC chr8:28173732-28174847 7 1.27 x 10-7 -0.07 0.43 0.39 -0.04 0.48 0.47 -0.01 0.4693 
KALRN chr3:124303035-124303404 4 3.34 x 10-6 -0.07 0.22 0.16 -0.05 0.15 0.15 -0.01 0.4072 
 
 
Table 2: Associations of DMR methylation and patient post-treatment survival 
   
DMR HR 95% CI PFDR  
HOXA4 3.48 1.71 – 7.08 0.0445 * 
SLCO3A1 2.43 1.26 - 4.68 0.0446 * 
MAFB 2.34 1.19 - 4.59 0.0445 * 
ADAMTS17 2.12 1.10 – 4.07 0.0607  
ZNF503 1.96 0.91 – 4.22 0.1660  
MYRIP 1.95 1.01 – 3.74 0.0820  
CDK6 1.88 0.96 - 3.66 0.0820  
BEND6 1.77 0.65 – 4.84 0.1660  
DAGLA 1.74 0.79 - 3.82 0.1390  
 
 
 




